The FDAs Next Call on an Alzheimers Drug Is Due This Week
Biogen and Eisai are jointly developing lecanemab. A decision on accelerated approval is expected by Friday....…
27,185€
2,93%
Echtzeit-Aktienkurs Eisai Co. Ltd.
Bid:
Ask: